CONMED CORP
CNMDNYSETrading Snapshot
- Day Range
- $43.50 β $46.09
- 52-Week Range
- $31.44 β $53.66
- Volume (shares)
- 157,196
- Avg Volume (shares)
- β
- Shares Outstanding
- 30.0M
- Next Earnings
- 2027-02-03
Fundamentals Snapshot
- Annual Revenue
- $1.37B
- Last Q Revenue
- $343M
- P/E Ratio
- 18.7
- P/S Ratio
- 1.0x
- EPS (TTM)
- $2.45
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β0.3%
CONMED CORP
CNMDAbout CONMED CORP
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

CONMED Q3 Earnings Call Highlights
CONMED NYSE: CNMD reported third-quarter 2026 revenue of $335.6 million, with organic constant-currency sales growth of 6.7% as the medical technology company cited broad-based contributions from its general surgery and

CONMED Corporation (CNMD) Q3 2026 Earnings Call Transcript
CONMED Corporation ( CNMD ) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDT Company Participants Patrick Beyer - President, CEO & Director John Gallagher - Executive VP, CFO and Principal Financial & Accounting Office

Conmed (CNMD) Q3 Earnings Top Estimates
Conmed (CNMD) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $1.08 per share a year ago.

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est

CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026. Third Quarte

Is Conmed Corp (CNMD) a Bargain After 6.0% Drop? GF Value Says Undervalued
On October 06, 2026, Conmed Corp (CNMD) shares fell 6.0% to a current price of $44.48, marking a significant decline in the context of a 52-week range of $31.44